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ABSTRACT The metabolism of lactate impacts infant gut health and may lead to
acute accumulation of lactate and/or H2 associated with pain and crying of colicky
infants. Because gut microbiota studies are limited due to ethical and safety con-
cerns, in vitro fermentation models were developed as powerful tools to assess
effects of environmental conditions on the gut microbiota. In this study, we
established a continuous colonic fermentation model (PolyFermS), inoculated with
immobilized fecal microbiota and mimicking the proximal colon of 2-month-old in-
fants. We investigated the effects of pH and retention time (RT) on lactate metabo-
lism and of lactate-utilizing bacteria (LUB) exhibiting little or no H2 production. We
observed that a drop in pH from 6.0 to 5.0 increased the number of lactate-
producing bacteria (LPB) and decreased LUB concomitantly with lactate accumula-
tion. Increasing RT from 5 to 10 h at pH 5.0 resulted in complete lactate consump-
tion associated with increased LUB. Supplementation with DL-lactate (60 mM) to
mimic lactate accumulation promoted propionate and butyrate production with no
effect on acetate production. We further demonstrated that lactate-utilizing Propi-
onibacterium avidum was able to colonize the reactors 4 days after spiking, suggest-
ing its ability to compete with other lactate-utilizing bacteria producing H2. In con-
clusion, we showed that PolyFermS is a suitable model for mimicking young infant
colonic microbiota. We report for the ﬁrst time pH and RT as strong drivers for com-
position and metabolic activity of infant gut microbiota, especially for the metabo-
lism of lactate, which is a key intermediate product for ecology and infant health.
IMPORTANCE The metabolism of lactate is important for infant gut health and may
lead to acute lactate and/or H2 accumulation, pain, and crying as observed in colicky
infants. Functional human studies often faced ethical challenges due to invasive
medical procedures; thus, in this study, we implemented PolyFermS fermentation
models to mimic the infant proximal colon, which were inoculated with immobilized
fecal microbiota of two 2-month-old infants. We investigated the impact of pH, re-
tention time, and accumulation of DL-lactate on microbiota composition and meta-
bolic activity. We found that a drop in pH from 6.0 to 5.0 led to increased LPB and
decreased LUB concomitantly with lactate accumulation. Increasing the RT resulted
in complete lactate consumption associated with increased LUB. Our data highlight
for the ﬁrst time the impact of key abiotic factors on the metabolism of lactate,
which is an important intermediate product for ecology and infant health.
KEYWORDS in vitro model, infant gut microbiota, infantile colic, lactate-utilizing
bacteria, pH, retention time
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The early establishment of gut microbes plays a crucial role in lifelong health anddisease of infants (1). After birth, the infant gut becomes home to many microbes
sourced from the mother and the environment. Primary colonizers are mainly lactate-
producing bacteria (LPB) belonging to the genera Biﬁdobacterium, Lactobacillus, Bac-
teroides, Streptococcus, Staphylococcus, and Enterococcus (2–4). Hence, lactate is pro-
duced in large amounts from metabolism of dietary nondigestible (human milk
oligosaccharides) and undigested (lactose) sugars and host mucins. Lactate is an
important intermediate substrate for the gut microbiota that feeds lactate-utilizing
bacteria (LUB). By combining detailed taxonomic (molecular) and functional (culture)
assessment, we recently reported the importance of metabolic cross-feeding of lactate
of the infant gut microbiota during the ﬁrst 6 months of life and identiﬁed keystone
species involved with lactate utilization (4). Moreover, lactate accumulation and me-
tabolism were associated with infant gut health (5).
Infantile colic, or excessive crying of unknown cause, is a functional gastrointestinal
disorder that affects up to 20% of infants (6, 7). In a recent study, colic phenotype was
correlated positively with speciﬁc groups of Proteobacteria, including Escherichia, Kleb-
siella, Serratia, Vibrio, and Pseudomonas, but negatively with Bacteroidetes and Firmic-
utes phyla in the ﬁrst weeks of life. A less diverse fecal microbiota was also observed in
infants with colic (8). We recently reported speciﬁc LUB signatures for colicky and crying
infants, supporting the hypothesis that increased H2 production by LUB could result in
acute H2 accumulation, leading to pain and crying as observed for colicky infants (5).
However, the huge interindividual variability of microbial composition poses a chal-
lenge to linking differences in the infant gut microbiota with health, symptoms, and
disease. Moreover, sampling of the gut contents, particularly in the highly fermentative
environment of the proximal colon, is highly restricted, especially for infants, due to
ethical, accessibility, and safety concerns.
Alternatively, in vitro fermentation models were developed as powerful tools to
study the effects of intrinsic and extrinsic factors on the composition and activity of
human gut microbiota uncoupled from the host. Different systems, from simple
anaerobic batch culture systems in ﬂasks to multistage continuous ﬂow models, have
been developed to model fermentation in the colon, which harbors the highest density
of microbes. However, colonic models should be carefully selected, with consideration
given to their features and limits related to the scientiﬁc question addressed (9, 10).
Inoculation of all fermentation models requires large amounts of fecal slurries, which is
the most important limitation to infant colonic modeling. The composition, diversity,
and function of infant gut microbiota in the ﬁrst months of life largely differ from those
of adults. The most profound differences are the elevated fecal lactate concentrations
and the absence of or very low fecal butyrate levels, correlated with a low abundance
of butyrate-producing bacteria (BPB) in infants, compared to the adult gut (4). Due to
the rapid depletion of substrate and reduction of pH, which prevent further microbial
activity, batch fermentation experiments are often restricted to short-term incubations.
Continuous culture models are necessary to perform long-term studies under pseudo-
steady-state conditions, with substrate replenishment and toxic product removal (10).
However, one of the main challenges of the continuous culture model is reproduc-
ing the high bacterial cell density and bioﬁlm-associated microbes of the gut that are
important to prevent washout of less-competitive bacteria. To address this, gut micro-
biota were immobilized in polysaccharide gel beads, starting from a small fecal
inoculum volume, to mimic different hosts while maintaining high bacterial diversity
and at cell densities in continuous intestinal reactors operating up to 120 days (11–15).
Immobilized cell models mimicking the proximal colon of 4- to 8-month-old infants
were successfully used to investigate the impact of retention time (RT) (16), prebiotics
(17), and nucleosides and yeast extracts (15). To our knowledge, due to the technical
difﬁculties of starting from small amounts of fecal samples, a fermentation model
mimicking very young infant gut microbiota has not yet been implemented.
To gain insights into lactate metabolism, which plays an important role in infant gut
health, we developed and validated for the ﬁrst time a continuous fermentation model
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inoculated with immobilized fecal microbiota to mimic 2-month-old formula-fed infant
gut microbiota. Using this model with the PolyFermS platform (12), we investigated the
effect of important parameters (pH and RT) for lactate metabolism on the gut micro-
biota composition and activity. Furthermore, because lactate is an important interme-
diate product associated with infant colic, we investigated accumulation of lactate by
supplementing DL-lactate and two infant lactate-utilizing bacterial strains (Propionibac-
terium avidum and Eubacterium limosum), selected for little or no H2 production, for
their potential to colonize and metabolize residual lactate. A recent classiﬁcation of the
genus Propionibacterium allocated the cutaneous P. avidum to the new genus Cutibac-
terium (18).
RESULTS
Colonization of donor fecal microbiota in fermentation model. Two PolyFermS
continuous fermentation models were used in this study to mimic the conditions in the
proximal colon of a 2-month-old formula-fed infant. The fermentation setup consisted
of a ﬁrst inoculum reactor (IR) inoculated with 30% (vol/vol) gellan-xanthan gel beads
that immobilized the fecal microbiota, which was connected to a control reactor (CR)
and four treatment reactors (TRs). All TRs and the CR were operated in parallel,
continuously inoculated with 5% fermentation efﬂuent from the IR, and additionally fed
with 95% fresh medium, as presented in Materials and Methods and illustrated in
Fig. 1a. After an initial colonization and stabilization time of 11 days, the fermentations
inoculated with fecal beads from donor 1 (fermentation F1) or donor 2 (fermentation
F2) were divided into two experimental periods. Detailed experimental conditions for
F1 and F2 with total times of 79 and 57 days, respectively, are depicted in Fig. 1b.
During period 1, the effects of three levels of pH (5.0, 6.0, and 7.0) and two RTs (5 and
10 h) were studied. The effects of lactate supplementation (60 mM DL-lactate) and LUB
strain addition on composition and activity of infant gut microbiota were investigated
during period 2. Each period consisted of stabilization with CR control conditions for 11
to 23 days, followed by treatment application for 8 to 14 days.
Feces from two 2-month-old healthy infant donors with similar gestational ages,
birth weights, ages, and feeding practices (see Table S1a in the supplemental material)
were used for immobilization and model inoculation. The microbial composition of
donor fecal samples was determined using qPCR targeting the 16S rRNA gene of
speciﬁc characteristic bacterial groups for the infant gut microbiota (Table 1). The two
selected donors harbored similar levels of Firmicutes and Bacteroides. Compared to
donor 2, the fecal sample from donor 1 harbored higher levels of Enterobacteriaceae
(9.4 and 7.9 log gene copies g1, respectively), Biﬁdobacterium (9.2 and 7.6 log gene
copies g1), Veillonella (9.4 and 8.6 log gene copies g1), and Lactobacillus (9.1 and 6.0
log gene copies g1).
The IR and CR were operated under constant conditions at pH 6.0 with an RT of 5 h
during the entire experiment and used for testing stability over 79 and 57 days in F1
and F2, respectively. After the ﬁrst stabilization time that allowed gut microbiota to
colonize the reactors and to reach steady conditions, the microbiota composition of the
IR and CR detected by qPCR during both fermentations was very similar to the
corresponding donor fecal sample for most of the targeted groups, including Firmic-
utes, Bacteroides, and Biﬁdobacterium (Table 1). Differences were observed for the levels
of Enterobacteriaceae, which were 1.5 log lower in the IR (7.9 log gene copies ml1) and
0.8 log lower in the CR (8.6 log gene copies ml1) compared to the donor 1 fecal
sample (9.4 log gene copies g1). Also, 1.5- and 2.3-log-higher levels of Veillonella were
detected in the IR (10.1 log gene copies ml1) and CR (10.9 log gene copies ml1)
compared to the donor 2 fecal sample (8.6 log gene copies g1), respectively.
Fermentation stability. To measure the metabolic and compositional stability of
both fermentation models, we performed HPLC, qPCR, and MiSeq sequencing analyses
of efﬂuent samples of the IR and CR of F1 and F2. The metabolite ratios and concen-
trations for short-chain fatty acids (SCFAs; acetate, propionate, and butyrate), lactate,
and formate measured with HPLC indicated overall stable microbial metabolic proﬁles
Lactate Metabolism in Infant Colon Fermentation Model
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in the IR and CR of both fermentations after an initial colonization and stabilization
period of 17 days (Fig. S1). During F1, we observed an effect of time where the acetate
concentration decreased (day 22, 128.8 mM; day 79, 94.7 mM) and the butyrate con-
centration increased (day 29, 8.1 mM; day 79, 21.6 mM), while the total C-mol concen-
tration (mole of carbon per liter) calculated from addition of all metabolites remained
stable (Fig. S1). These data suggest that the observed time drift in F1 is associated not
with a loss of metabolic activity but instead with discrete equilibration of metabolism,
with more acetate, as an intermediate metabolite, being converted into butyrate.
Acetate was the main metabolite in efﬂuents of both fermentations, followed by
propionate and butyrate. While formate was not detected in the IR and CR of F1, it
represented a signiﬁcant fraction of approximately 20% (20 mM) of the total metab-
olites of F2. The propionate concentration was lower, while the butyrate concentration
was higher, in the IR and CR of F1 compared to F2. Furthermore, qPCR data showed
stability of the bacterial groups of infant microbiota that were analyzed, including
Firmicutes, Enterobacteriaceae, Bacteroides, Biﬁdobacterium, Veillonella, and Lactobacillus
(Fig. S2). The model stability was conﬁrmed by MiSeq data that showed an overall
stable relative abundance of microbiota at the genus level in both reactors, with some
ﬂuctuations in the relative abundance of Ruminococcus, Veillonella, and Prevotella
(Fig. S3).
FIG 1 (a) Setup of the PolyFermS fermentation model inoculated with immobilized infant gut microbiota. The fermentation setup consisted of an inoculum
reactor (IR) containing 30% (vol/vol) fecal beads, connected to a control reactor (CR) and four treatment reactors (TRs) continuously fed with 5% fermentation
efﬂuent from the IR and 95% fresh medium. All reactors were constantly ﬂushed with CO2 to maintain anaerobiosis. Temperature was set at 37°C, stirring speed
was set at 180 rpm, and pH was controlled automatically by the addition of 2.5 M NaOH. All reactors had a total working volume of 200 ml. (b) Setup of the
experiment conditions at different periods. The fermentation of fecal samples from donor 1 (fermentation 1) and donor 2 (fermentation 2) was divided into
2 periods; each period consisted of stabilization and treatment and washout. RT, retention time; LUB, lactate-utilizing bacteria.
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No signiﬁcant differences in composition and metabolic activity of the microbiota
between the CR and TRs after the stabilization period were found in both fermentations
(Fig. S4).
In conclusion, qPCR detected similar levels of predominant groups for donor sam-
ples and the IR and CR. Differences in bacterial levels detected for the 2 donor fecal
samples were well reproduced in the IR and CR of F1 and F2 and are reﬂected in distinct
metabolic proﬁles. After an initial stabilization time of 17 days, we also demonstrated
high stability of composition and metabolic activity of the microbiota over 79 and
57 days of continuous operation in the IR and CR operated with constant conditions for
both F1 and F2, respectively.
Impact of pH. During period 1 stabilization, all reactors were set at pH 6.0 and an
RT of 5 h. Combinations of different pHs and RTs were then assigned to TRs during the
following treatment period while CR conditions were kept constant (Fig. 1b). The pHs
5.0 and 7.0 were chosen to mimic the colonic pH of breast-fed (fecal pH 5.1 to 5.4 in
the ﬁrst 6 weeks) and formula-fed (fecal pH 7.0 to 8.2 from the second to the ﬁfth week;
fecal pH 6.4 after the ﬁfth week) infants, respectively (19). For the statistical analysis of
qPCR and metabolite data pooled from the two fermentations F1 and F2 inoculated
with different microbiota, we calculated differences (delta) between treatment and
previous stabilization period for each reactor. We compared the delta values of each
treatment reactor (TR1 to TR4) with that of the control reactor (CR) measured during the
same periods, using the nonparametric Wilcoxon rank sum test with false-discovery
rate correction. Reducing the pH from 6.0 to 5.0 led to a signiﬁcant increase in lactate
(P 0.001), and decreases in propionate (P 0.001), isobutyrate (P 0.001), and bu-
tyrate (P 0.001) production at pH 5.0 compared to pH 6.0 were shown (Fig. 2a). For
both fermentations, signiﬁcant lactate accumulation (from 0.6 0.1 to 54.9 3.9 mM
in F1; from 0.0 to 47.7 8.0 mM in F2; P 0.01) and signiﬁcantly decreased propionate,
butyrate, and isobutyrate (P 0.01 for F1 and P 0.05 for F2) production were
measured at pH 5.0 compared to pH 6.0 (Fig. S5a and b). Moreover, a pH of 5.0 resulted
in decreased acetate in F1 (P 0.001) or formate in F2 (P 0.05) relative to pH 6.0.
Signiﬁcantly lower levels of Veillonella (P 0.01) and Bacteroides (P 0.001) and higher
levels of Lactobacillus (P 0.001) and Enterobacteriaceae (P 0.001) were measured
using qPCR for efﬂuent samples at pH 5.0 compared to pH 6.0 when combining data
from the two fermentations (Fig. 3a) with fermentation (donor) effects (Table 1).
Furthermore, lower relative abundances of Veillonella (F1, 1.5% versus 9.2%; F2, 1.2%
versus 17.3%) and Prevotella (F1, 0.5% versus 5.7%; F2, 1.4% versus 5.4%) and higher
relative abundances of Lactobacillus (F1, 22.2% versus 0.5%; F2, 2.8% versus 0.03%),
Enterococcus (F1, 12.2% versus 4.4%; F2, 32.8% versus 1.0%), and Biﬁdobacterium (F1,
41.7% versus 30.5%; F2, 47.6% versus 3.5%) were recorded for both fermentations at pH
5.0 compared to pH 6.0 using MiSeq; however, no sequencing replicates prevent
statistical analysis on MiSeq data (Fig. 4). During F1, low relative abundances of
Ruminococcus (0.19% versus 19.3%) and Peptostreptococcaceae (0.19% versus 7.2%) and
high relative abundances of Citrobacter (7.6% versus 2.8%) and Enterobacteriaceae
(11.0% versus 6.6%) were measured at pH 5.0 compared to pH 6.0 (Fig. 4a). On the other
hand, a strong decrease of the relative abundances of Collinsella (5.9% versus 29.9%)
and Bacteroides (2.3% versus 21.4%) was observed in F2 at pH 5.0 compared to 6.0
(Fig. 4b).
Analysis of pooled data from the two fermentations showed a signiﬁcant decrease
in acetate (P 0.001) and an increase in butyrate (P 0.05) (Fig. 2b) and a signiﬁcant
increase in Enterobacteriaceae (P 0.001), Firmicutes (P 0.001), Veillonella (P 0.001),
Bacteroides (P 0.05), and total bacteria (P 0.01) at pH 7.0 compared to pH 6.0
(Fig. 3b). The impact of the high pH of 7.0 (TR3) on microbial composition and
metabolic activity was fermentation (donor) dependent (Table 1; Fig. S5c and d). No
signiﬁcant effect of pH 7.0 on either microbial composition or metabolic activity was
found in F2 compared to pH 6.0. In contrast, during F1, pH 7.0 signiﬁcantly decreased
acetate production (P 0.01) and Firmicutes and Biﬁdobacterium levels (P 0.05) and
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FIG 2 Effect of pH (a and b) and retention time (RT) (c) on the metabolic activity of infant gut microbiota using data from both
fermentations. Values are expressed as differences (delta) of SCFA concentrations (mM) between treatment and previous stabilization
period within each reactor.
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increased butyrate (P 0.01) and formate (P 0.05) accumulation compared to pH 6.0.
Lower relative abundances of Biﬁdobacterium and Prevotella and higher relative abun-
dances of Enterococcus were also observed in both fermentations at pH 7.0 compared
to 6.0 (Fig. 4a and b). Furthermore, the relative abundance of Anaerococcus increased
FIG 3 Effect of pH (a and b) and retention time (RT) (c) on levels of speciﬁc bacterial groups enumerated by qPCR using data from
both fermentations. Values are expressed as differences (delta) of log10 16S rRNA gene copy numbers of speciﬁc bacterial groups
enumerated by qPCR between treatment and previous stabilization period within each reactor.
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FIG 4 Impact of pH; retention time (RT) at pH 6.0; retention time (RT) at pH 5.0; and addition of lactate, E. limosum, and P. avidum on the
relative abundance of 16S rRNA genes at genus level analyzed in fermentation efﬂuent using Illumina MiSeq in fermentations 1 (a) and
2 (b). When assignment at genus level was not possible, the highest-level taxonomy assignment was shown.
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and that of Veillonella decreased during F1, while Bacteroides and Streptococcus in-
creased and Collinsella decreased during F2, at pH 7.0 compared to pH 6.0, although no
statistical testing could be done.
Impact of retention time. The effect of RT (5 and 10 h) on the gut microbiota
composition and metabolic activity was tested at pH 6.0 in TR2 of both models during
experimental period 1 (Fig. 1b). An RT of 10 h signiﬁcantly increased butyrate produc-
tion (P 0.001) compared to 5 h with pooled data from both fermentations (Fig. 2c)
and by 4-fold and 2.5-fold in F1 and F2, respectively (Fig. S6a and b). A longer RT also
led to signiﬁcantly lower acetate in F1 (P 0.05) and total metabolite (P 0.01) levels
compared to an RT of 5 h (Fig. S6a). A 10-h RT signiﬁcantly increased total bacteria
(P 0.01), Firmicutes (P 0.05), Enterobacteriaceae (P 0.01), and Bacteroides
(P 0.001) when pooling data from the two fermentation (Fig. 3c). We also measured
decreased Biﬁdobacterium (P 0.05) and Veillonella (P 0.05) in F1 compared to those
with a 5-h RT (Table 1). In contrast, no impact of RT was found for the microbial
composition of F2 using qPCR. However, decreased Biﬁdobacterium and increased
Enterobacteriaceae abundances during F1 and at 10-h RT compared to 5-h RT were
conﬁrmed by MiSeq data (Fig. 4a and b). Furthermore, lower Ruminococcus and higher
Anaerococcus abundance during F1, lower Streptococcus abundance during F2, and
higher Prevotella abundance during both fermentations were observed at the 10-h RT
than at the 5-h RT (Fig. 4a and b).
We also compared TR1 (pH 5.0; RT, 5 h) and TR4 (pH 5.0; RT, 10 h) during period 1,
because similar conditions were used for all TRs during the stabilization period,
resulting in similar microbiota composition and activities (Fig. S4). At pH 5.0, a 10-h RT
signiﬁcantly decreased lactate accumulation compared to a 5-h RT (P 0.001) in both
fermentations (Fig. S6c and d). MiSeq data showed a trend for higher relative abun-
dance of lactate-producing Enterococcus in both fermentations at 10-h RT compared to
5-h RT. Moreover, a lower abundance of Lactobacillus and higher abundances of
Biﬁdobacterium, Enterococcus, and Anaerococcus during F1 were observed at 10-h RT
compared to 5-h RT at pH 5.0 (Fig. 4b). In contrast, a lower abundance of Biﬁdobacte-
rium and a higher abundance of Collinsella and Veillonella were observed during F2 at
10-h RT compared to 5-h RT at pH 5.0 (Fig. 4b).
Impact of DL-lactate supplementation. Supplementation with 60 mM DL-lactate in
nutritive medium to mimic the accumulation of lactate in the infant gut resulted in
signiﬁcant lactate accumulation (P 0.001) as well as an increase in acetate (P 0.001),
propionate (P 0.001), and total SCFA (P 0.001) production compared to no supple-
mentation, when combining data from the two fermentations (Fig. 5a). Lactate accu-
mulations in the efﬂuent were similar, of 11.7 1.9 mM and 12.8 2.7 mM for F1 and
F2, respectively. Signiﬁcant fermentation (donor)-dependent increases in propionate
and butyrate were detected (Fig. S7a and b). L-Lactate determination by enzymatic
assay revealed the presence of both D- and L-isomers of lactate in reactors supple-
mented with 60 mM DL-lactate in F1 (47.9 and 52.1%, respectively) and F2 (71.5 and
28.5%). No signiﬁcant effect of lactate supplementation on microbial composition by
qPCR was observed (Table 1 and Fig. 6a), except for a small but signiﬁcant decrease of
Eubacterium hallii (P 0.05) with addition of lactate. In contrast, adding 60 mM DL-
lactate appeared to affect microbial relative abundances of some groups, with ob-
served increased Peptostreptococcaceae (10.9% versus 7.1%) and decreased Citrobacter
(0.6% versus 3.9%) and Enterobacteriaceae (4.2% versus 11.3%) abundances in F1, and
increased Collinsella (43.4% versus 29.3%) and Veillonella (22.8% versus 14.0%) and
decreased Bacteroides (5.7% versus 14.1%) and Enterococcus (1.5% versus 8.8%) abun-
dances in F2 (Fig. 4).
Impact of addition of lactate-utilizing bacteria with DL-lactate supplementa-
tion. P. avidum or E. limosum was selected among infant LUB for its capacity to utilize
lactate with no or little H2 production, respectively. We tested the impact of daily
spiking with each strain individually at a high cell concentration (108 CFU ml1) in
reactors supplemented with 60 mM DL-lactate to mimic lactate accumulation.
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E. limosum was detected at high levels in F1 and F2 (8.9 0.2 and 7.8 0.4 log
copies ml1, respectively) in reactors 22 h after spiking (Table 2 and Fig. 6c). When
pooling data from the two fermentations, E. limosum and lactate supplementation led
to signiﬁcant increases in lactate (P 0.01), formate (P 0.05), propionate (P 0.001),
FIG 5 Effect of the addition of lactate (a) and of lactate and lactate-utilizing bacteria (b and c) on the metabolic activity of infant gut
microbiota using data from both fermentations. Values are expressed as differences (delta) of SCFA concentrations (mM) between
treatment and previous stabilization period within each reactor.
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FIG 6 Effect of the addition of lactate (a) and of lactate and lactate together with lactate-utilizing bacteria (b and c) on levels of speciﬁc
bacterial groups enumerated by qPCR using data from both fermentations. Values are expressed as differences (delta) of log10 16S rRNA
gene copy numbers of speciﬁc bacterial groups enumerated by qPCR between treatment and previous stabilization period within each
reactor.
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and total SCFAs (P 0.001) (Fig. 5c). The impact of daily addition of E. limosum at 108
CFU ml1 together with 60 mM DL-lactate differed between fermentations (Fig. S7c
and d). E. limosum and lactate supplementation signiﬁcantly increased butyrate
(30.3 1.3 mM versus 18.7 1.2 mM, P 0.01) in F1 and propionate (20.6 2.5 mM
versus 11.2 2.9, P 0.05) in F2 compared to respective stabilization. This treatment
also decreased Enterobacteriaceae detected by qPCR in F1 (P 0.05) (Table 2), which
was conﬁrmed by MiSeq data in both fermentations. A lower abundance of Enterococ-
cus was also observed in both fermentations, with a higher relative abundance of
Biﬁdobacterium, Peptostreptococcaceae, and Ruminococcus during F1 and of Collinsella
and lactate-utilizing Veillonella during F2 and a lower Bacteroides abundance during F2
(Fig. 4).
Due to the lack of speciﬁc primers for Propionibacterium, we quantiﬁed P. avidum by
speciﬁc plating of efﬂuent samples of all reactors during stabilization, after daily spiking
with 1 108 (TR3) or 5 108 (TR4) CFU ml1 P. avidum and during the washout period
after the treatment during F2 (Fig. S8a). Before treatment, P. avidum viable cell counts
were similar and low in all reactors (4.1 0.4 log CFU ml1). P. avidum reached similar
high cell counts of 8.6 0.9 log CFU ml1 (TR3) and 8.4 0.1 log CFU ml1 (TR4) for
the two addition levels. Interestingly, 4 days after the last P. avidum addition, signiﬁ-
cantly higher levels were detected in TR3 and TR4 by plate counts (6.7 0.3 and
5.9 0.4 CFU ml1, respectively) compared to nontreated reactors (TR1, 4.8 0.1 CFU
ml1; TR2, 4.0 0.1 CFU ml1) (P 0.001; except TR4 versus TR1, P 0.05).
The addition of P. avidum at 108 CFU ml1 together with 60 mM DL-lactate resulted
in a signiﬁcant increase of lactate (P  0.001), acetate (P  0.001), propionate
(P 0.001), and total metabolite (P 0.001) production when combining data from the
two fermentations (Fig. 5b). In F1, this treatment also led to increased butyrate
concentration (P 0.001), decreased Enterobacteriaceae (0.5 log copy number), and
increased E. limosum (1.5 log copy number) (Table 2 and Fig. S7e). Combining data from
the two fermentations indicated signiﬁcant increase in Veillonella (P 0.01) and de-
crease in E. hallii (P 0.05) levels after the addition of P. avidum and lactate compared
to stabilization with this treatment (Fig. 6b). Trends toward higher Anaerococcus and
Ruminococcus and lower Enterococcus abundances were also observed during F1
(Fig. 4).
Compared to 60 mM DL-lactate, the addition of 108 CFU ml1 P. avidum together
with 60 mM DL-lactate led to a decrease in lactate (P 0.001) and an increase in E.
limosum (P 0.05) (Fig. 7a and c). Addition of 108 CFU ml1 E. limosum together with
60 mM DL-lactate decreased lactate (P 0.001) and acetate (P 0.05) and increased
levels of E. limosum (P 0.001) and E. hallii (P 0.05) compared to 60 mM DL-lactate
alone (Fig. 7d).
To further demonstrate the impact of treatments on the infant PolyFermS microbi-
ota of donors 1 and 2, we performed principal-coordinate analysis (PCoA) of weighted
and unweighted UniFrac distance (Fig. S9). In fermentation 2, PCoA showed a clear
separation of the treated microbiota from the untreated control, whereas this separa-
tion was less clear in fermentation 1.
DISCUSSION
PolyFermS closely mimics the young infant gut microbiota. The initial coloniza-
tion of the gut is important for both short- and long-term health of infants (3). Infant
gut microbiota studies using 16S rRNA-based analysis of fecal samples have provided
crucial data on the composition and diversity of the gut microbiota and the effects of
many factors, such as delivery mode (20) and diet (21). However, molecular methods
can provide only limited insights into mechanisms and functions of bacterial species.
Moreover, functional in vivo studies in humans often face social and ethical challenges
due to invasive medical procedures (9, 10). In this study, for the ﬁrst time we reported
gut fermentation models to mimic the proximal colon of a 2-month-old infant and
investigated the impact of abiotic and biotic factors to modulate infant gut microbiota
composition and metabolic activity.
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FIG 7 Effect of the addition of lactate-utilizing bacteria on the metabolic activity of infant gut microbiota (a
and b) and on levels of speciﬁc bacterial groups enumerated by qPCR (c and d) using data from both
fermentations. Values are expressed as differences (delta) of SCFA concentrations (mM) and log10 16S rRNA
gene copy numbers of speciﬁc bacterial groups enumerated by qPCR between treatment and previous
stabilization period within each reactor.
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Large individual variations in gut microbiota composition and diversity in the ﬁrst
months of life have been well demonstrated in recent studies (2, 4, 21). The two infant
donors used to inoculate the PolyFermS models harbored very different microbial
compositions and in vitro metabolic proﬁles. The levels of Enterobacteriaceae, Bacte-
roides, Biﬁdobacterium, Lactobacillus, and total bacteria of the two infant donors were
within the ranges reported in previous publications (17, 22–24). Distinct microbial
compositions of fecal inoculum samples were reﬂected in different microbial compo-
sitions and metabolic activities of the microbiota during fermentations, such as high
propionate-producing Veillonella levels together with high propionate production for
donor 2 and in the IR and CR of F2, compared to donor 1 and F1.
The levels of predominant bacterial groups detected by qPCR in the IR and CR, with
the exception of Veillonella, were similar to the corresponding donor fecal samples,
suggesting that the gut microbiota from donor fecal samples were well conserved
during sampling, immobilization, and cultivation under the conditions selected for the
formula-fed young infant model. The preparation of the bead inoculum used only small
amounts of fecal microbiota which could be obtained from ca. only 1 g of fecal material
for production of approximately 200 ml of beads, and only 60 ml of beads was required
for inoculation of the IR. This, with the reproduction of both the planktonic and sessile
microbiota of the colon, is a unique feature of immobilization and using PolyFermS for
modeling young, and possibly preterm, infant gut microbiota when only very limited
volumes of feces are available. High and stable microbial concentrations, and stable
relative abundances comparable to the fecal sample, were measured in the IR and CR
throughout the 79- and 57-day fermentations. These data, combined with SCFA data,
indicate long-term stability of fermentation models inoculated with infant fecal beads.
PolyFermS models can be expanded to various conﬁgurations, allowing comparison of
treatments and a control with the same microbiota (12, 13, 15, 25). In this study, the
PolyFermS model, which combines four treatments with a control reactor operated
with constant conditions and inoculated with identical microbiota as produced in the
IR, appears well suited for testing a range of abiotic and biotic factors of infant gut
fermentation and requires only a minimal amount of fecal material for inoculation.
Low pH increased LPB and decreased LUB concomitantly with lactate accumu-
lation. In vitro fermentations with fecal inocula from 6-month-old infants, children, and
adults have demonstrated the impact of environmental conditions, such as pH and RT,
on the gut microbiota composition and lactate metabolism (12, 16, 26, 27). Little is
known about the impact of such factors on the gut microbiota of younger infants,
mainly because suitable gut fermentation models were lacking. Furthermore, lactate is
one of the most important intermediate metabolites in the infant gut, and its accu-
mulation can be detrimental for health (28). Using PolyFermS models, we investigated
the impact of colonic pH and RT, which are known to vary widely in infants, and
simulated lactate accumulation to determine the impact on 2-month-old infant gut
microbiota and lactate metabolism.
The colonic pH can have a profound effect on the composition and metabolic
activity of the human gut microbiota. A study investigating the effects of pH (5.2, 5.9,
and 6.4) on lactate production and utilization in batch cultures inoculated with fecal
slurries from four adult donors showed that pH 5.2 induced lactate accumulation due
to reduced utilization (27). Using a single-stage continuous model inoculated with
immobilized 6-month-old infant fecal microbiota, Cinquin et al. reported that the
proportion of lactate signiﬁcantly decreased when both the pH and RT were increased
simultaneously, mimicking conditions from proximal to distal colon (16). Lactate utili-
zation plays a central role in the metabolism of infant gut microbiota and could have
a direct impact on infant health (4, 5, 29). To our knowledge, this is the ﬁrst study
investigating the impact of pH on infant gut microbiota composition and metabolic
activity using in vitro colonic fermentation models. The selection of pH 5.0, 6.0, and 7.0
in this study was physiologically relevant, considering that infant stool pH varies from
4.8 to 7.0 in the ﬁrst month of life (30). A recent study investigating the effect of
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Biﬁdobacterium infantis supplementation on fecal pH showed that the mean fecal pH of
the probiotic group was 5.15, whereas the control group had a fecal pH of 5.97 (31).
One important ﬁnding in this study is the effect of low pH on fermentation under
conditions mimicking the infant proximal colon. A low pH of 5.0 led to lactate
accumulation and signiﬁcantly decreased propionate and butyrate production, which
agrees with data in adults (27). The decrease of propionate levels at pH 5.0 compared
to pH 6.0 could be explained by a lower abundance of Veillonella bacteria, which are the
main producers of propionate in the infant gut (4). Similarly, the decrease in butyrate
production at pH 5.0 may be associated with lower abundance of butyrate-producing
Anaerococcus. The accumulation of lactate at pH 5.0 agrees with the observed higher
abundance of LPB (i.e., Lactobacillus, Enterococcus, and Biﬁdobacterium) and lower
abundance of LUB (i.e., Veillonella). Consistent with previous studies (12, 26, 32), we also
observed an inhibition of Bacteroides by acidic pH, as shown by both qPCR and MiSeq
analyses.
Increasing RT resulted in complete lactate consumption at low pH, associated
with increased LUB. Formula-fed infants showed a large variation in gastrointestinal
transit time, with mean RTs of 13.7 h (range, 7.1 to 35.2 h) and 17.4 h (range, 5.4 to 36.5
h) at age 17 and 113 days, respectively (33), while the proximal colon transit time is
estimated to be about one-third of the total transit time. In this study, we demonstrated
that proximal colonic transit time is a strong determinant of the 2-month-old infant gut
microbiota composition and metabolism in vitro. We showed that the effect of RT is pH
and donor dependent. Increasing RT from 5 to 10 h at pH 5.0 attenuated the effect of
low pH on the gut microbiota composition and metabolic activity and reduced lactate
accumulation. This effect could be explained by the lower abundance of lactate-
producing Lactobacillus and the higher abundance of lactate-utilizing Veillonella upon
increased RT. We suggested that increased RT promotes the establishment of the
trophic chain and the reutilization of lactate. In agreement, a recent study using an in
vitro continuous fermentation system inoculated with adult fecal microbiota also
reported that the abundance of Veillonellaceae (including genus Veillonella) increased
with prolonged RT (34). Increasing RT from 5 to 10 h at pH 5.0 resulted in a small but
signiﬁcant increase of isobutyrate, suggesting an elevation of proteolytic activity
possibly due to carbohydrate limitations (35).
At pH 6.0, a 10-h RT led to a lower abundance of Biﬁdobacterium and a higher
abundance of Enterobacteriaceae relative to a 5-h RT. This observation agrees with
previous studies that showed that Biﬁdobacterium spp. were less abundant in feces
from functional constipated adult patients (36) and that Enterobacteriaceae levels were
higher and Biﬁdobacterium levels were lower in constipated-irritable bowel syndrome
(IBS) adults (C-IBS) compared to healthy adults (37). Increasing RT at pH 6.0 favored
butyrate production in both fermentations concomitantly with a decrease of the
intermediate products acetate (F1) and formate (F2). This observation could be ex-
plained by the slow kinetics and low levels of butyrate producers in the infant
microbiota, which cannot efﬁciently reuse intermediate products such as lactate,
succinate, and acetate when the RT is short. Our data provide initial mechanistic
insights into the possible impact of transit time on infant gut microbiota composition
and activity.
Supplementation with lactate and LUB reduced Enterobacteriaceae and in-
creased SCFAs. Because most primary colonizers in the infant gut are LPB, lactate must
be efﬁciently reused to prevent negative consequences of lactate accumulation. How-
ever, excess H2 production from lactate utilization (e.g., by Veillonella) may also lead to
ﬂatulence and is a possible factor in infantile colic (38). Indeed, we recently reported
higher lactate-utilizing, H2-producing bacteria in colicky infants (5). On the other hand,
LUB that produce only minimal or no H2 (e.g., E. limosum and P. avidum) were shown
to compete with high H2-producing LUB (e.g., Veillonella) in pure and mixed cultures
using anaerobic techniques (5).
In this study, a large amount of lactate (ca. 80% of 60 mM added DL-lactate) was
reused, conﬁrming the efﬁcient utilization of lactate by LUB. Furthermore, adding
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60 mM DL-lactate to mimic lactate accumulation increased butyrate and propionate
formation. Interestingly, the impact of lactate was detected only on a functional but not
on a taxonomic level, suggesting that lactate increased the activity of LUB by providing
more energetic substrate but not by stimulating growth to detectable levels. Infant LPB,
including Lactobacillus, produce both D- and L-lactate. The two isomers of lactate were
detected at comparable levels after the addition of 60 mM DL-lactate, suggesting that
the 2-month-old infant LUB community was able to utilize both D- and L- forms. Our
data suggest that LUB of infant colonic microbiota have a high capacity to metabolize
lactate, possibly as a natural protective mechanism in infant microbiota preventing
lactate accumulation and detrimental health effects such as acidosis.
The E. limosum and P. avidum strains tested in this study were isolated from healthy
infant feces and characterized for their ability to metabolize different substrates (5).
While E. limosum utilizes lactate to produce butyrate, P. avidum produces propionate,
acetate, and CO2. Lyophilized E. limosum fed to mice signiﬁcantly attenuated colitis and
increased cecal butyrate levels compared to the control group (5, 39). In our study, E.
limosum, combined with the supplementation with 60 mM DL-lactate, led to a lower
relative abundance of the Enterobacteriaceae family. The treatment also promoted
acetate and butyrate production in F1 and propionate in F2, consistently with the
butyrogenic and propionigenic proﬁles of donors 1 and 2, respectively. The increase of
propionate might be attributed to the addition of lactate, which further stimulates the
lactate-utilizing propionate-producing bacteria. The increase of butyrate and propi-
onate may be of clinical signiﬁcance for the infant gut, because of their well-established
beneﬁcial impacts on host health. Butyrate is the main energy source for enterocytes
and regulates the epithelial barrier and immunity functions of the epithelial cells (40,
41). Furthermore, butyrate has been implicated in protection against colitis and colo-
rectal cancer (42). On the other hand, propionate has been shown to stimulate an
anti-inﬂammatory response (43).
Propionibacterium, recently reclassiﬁed in two different genera, Propionibacterium
and Cutibacterium according to dairy and skin origin, respectively, is one of the
dominant organisms of the skin microbiota (44). Recent studies have reported its
natural occurrence in breast milk (45, 46), as well as in neonatal feces (47, 48). The
addition of P. avidum with 60 mM DL-lactate increased concentrations of both lactate
and the main SCFAs, decreased Enterobacteriaceae, and increased butyrate-producing
E. limosum by 1.5 log. The increase of butyrate could be explained by the increase of
E. limosum. Furthermore, P. avidum produces acetate, which could be used by butyrate
producers. Moreover, in comparison with the theoretical washout curves of P. avidum
spiked at 1  108 and 5 108 CFU ml1, calculated for a 5-h RT in a homogenous
continuous stirred-tank reactor (see Fig. S8b in the supplemental material), our data
demonstrated the ability of P. avidum to colonize the reactors 4 days after spiking.
In conclusion, we successfully implemented for the ﬁrst time stable continuous
colonic fermentation models to mimic the proximal colon of very young infants using
immobilized fecal microbiota. Using the PolyFermS model platform, we observed a
strong impact of pH and RT on the composition and metabolic activity of the gut
microbiota involved in lactate metabolism, which is important for ecology and infant
health. Using two different donors with different microbiota reﬂects the in vivo situa-
tion, where interindividual variability is inevitable and unavoidable and further
strengthens the impacts detected in both fermentations.
MATERIALS AND METHODS
Bacterial strains and growth conditions. P. avidum (strain 4118; Laboratory of Food Biotechnology,
ETH Zurich) was previously isolated from feces of a healthy infant (5). The strain was activated from
glycerol stocks (33%, 80°C) and routinely cultured under aerobic conditions at 37°C in a 1% (vol/vol)
concentration in sodium lactate broth, which was composed of 10 g liter1 Trypticase soy broth without
dextrose (Becton, Dickinson AG, Allschwil, Switzerland); 10 g liter1 yeast extract (Merck, Darmstadt,
Germany); 117 mM sodium DL-lactate 60% syrup (Central Drug House, New Delhi, India); 0.25 g liter1
KH2PO4 (VWR International AG, Dietikon, Switzerland); and 5 mg liter1 MnSO4, 4 mg liter1 metronida-
zole, and 10 mg liter1 kanamycin (all from Sigma-Aldrich, Buchs, Switzerland) in distilled water.
Overnight P. avidum cultures (200 ml and 1 liter for inoculation of 1 108 and 5 108 CFU ml1,
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respectively) were centrifuged at 7,000 rpm for 10 min, the supernatants were discarded, and the
bacterial pellets were washed with 0.1 N sodium phosphate buffer (6 g liter1 NaH2PO4, 7.1 g liter1
Na2HPO4; both from VWR International AG, Dietikon, Switzerland). The resuspended pellets were
centrifuged at 7,000 rpm for 10 min and resuspended in sodium phosphate buffer (10 and 20 ml,
respectively) before being added to the test reactors.
E. limosum (strain 4119; Laboratory of Food Biotechnology, ETH Zurich), previously isolated from feces
of a healthy infant (5), was activated from stabbed agar Hungate stocks (20°C). The strain was
subcultured daily at 3% (vol/vol) in YCFA medium supplemented with 60 mM DL-lactate (Sigma-Aldrich,
Buchs, Switzerland) at 37°C under strict anaerobiosis using Hungate tubes ﬂushed with CO2 (42, 49).
Twenty Hungate tubes containing 10 ml of overnight E. limosum cultures were prepared for inoculation
of 108 CFU ml1, by centrifugation at 2,000 rpm for 20 min and resuspension in 8 ml of prereduced
peptone water (10 g liter1 peptone, 5 g liter1 sodium chloride) before being used to inoculate the
reactors. The purity of P. avidum and E. limosum cultures was checked via Gram staining.
Fecal inoculum and immobilization. Two continuous colonic fermentation experiments were
performed independently. Fresh fecal samples were obtained from healthy 2-month-old infants born
without congenital disease. Because the composition of human milk is very complex and hence difﬁcult
to mimic in vitro, both infants selected for this study had been fed exclusively with infant formula (see
Table S1 in the supplemental material). Exclusion criteria were variables known to affect the balance of
the infant gut microbiota, including preterm birth, antibiotic usage, and gastrointestinal and immuno-
logical disorders during the neonatal period. The study was exempted by the Ethics Committee of ETH
Zurich because the fecal sample collection was noninvasive and not in terms of intervention. Informed
written consent was obtained from the mothers on behalf of the infants.
The fecal sample (ca. 5 g) was collected from diapers, immediately suspended in prereduced peptone
water (10 g liter1 peptone, 5 g liter1 sodium chloride), transferred into a gastight anaerobic jar
containing a CO2-generating system (Anaerocult A; VWR International AG, Dietikon, Switzerland), and
transported at 4°C for processing, immobilization, and reactor inoculation within 3 h of defecation.
Immediately upon receipt, the fecal sample was transferred to an anaerobic chamber and immobilized
in 1- to 2-mm-diameter gel beads composed of 2.5% (wt/vol) gellan gum, 0.25% (wt/vol) xanthan gum,
and 0.2% (wt/vol) sodium citrate as previously described (17).
Experiment setup and fermentation procedures. The fermentation medium was based on the
composition designed previously to mimic the chyme entering the colon of 6-month-old infants (17, 50).
The medium contained the following (g liter1): lactose (6.4), casein (0.5), whey protein (8.1), peptone
(0.5), Bacto tryptone (0.5), mucin (4), yeast extract (2.5), cysteine (0.8), bile salts (0.05), KH2PO4 (0.5),
NaHCO3 (1.5), NaCl (4.5), KCl (4.5), MgSO4·7H2O (1.25), CaCl2·2H2O (0.1), FeSO4·7H2O (0.005), hemin (0.01),
Tween 80 (1), and vitamin solution. The vitamin solution contained the following (mg liter1): pyridoxine-
HCl (100), 4-aminobenzoic acid (PABA) (50), nicotinic acid (50), biotin (4), folic acid (4), cyanocobalamin
(5), thiamine (50), riboﬂavin (50), phylloquinone (0.15), menadione (2), and D-pantothenic acid (100). The
nutritive medium was freshly prepared daily, autoclaved, and stored at 4°C under stirring until use. All
components were from Sigma-Aldrich (Buchs, Switzerland), except for whey protein (Emmi, Dagmer-
sellen, Switzerland), peptone (Oxoid AG, Pratteln, Switzerland), Bacto tryptone (Becton, Dickinson AG,
Allschwil, Switzerland), bile salts (Oxoid AG, Pratteln, Switzerland), and KH2PO4 (VWR International AG,
Dietikon, Switzerland).
The PolyFermS continuous fermentation model used in this study was designed to mimic conditions
in the proximal colon of a 2-month-old formula-fed infant. The fermentation setup consisted of a ﬁrst
reactor with a working volume of 200 ml inoculated with 60 ml (30%, vol/vol) fecal beads from the
respective donor (IR), which was connected to a control reactor (CR) and four test reactors (TRs) (Fig. 1).
All TRs and the CR (200-ml working volume) were continuously inoculated with 5% (vol/vol) fermentation
efﬂuent from the IR and fed with 95% fresh medium. To maintain anaerobiosis, all reactor headspaces
were constantly ﬂushed with CO2. Temperature was set at 37°C, stirring speed was set at 180 rpm, and
pH was maintained automatically at 6.0 by adding 2.5 M NaOH.
Initial batch fermentations were carried out at a temperature of 37°C and a pH of 6.0 with stirring
(180 rpm) to colonize beads in the IR. During colonization (days 1 and 2), fermentation efﬂuent was
replaced by fresh medium every 12 h (17). Afterward, the IR was switched to continuous mode at a ﬂow
rate of 40 ml h1, corresponding to a mean RT of 5 h. This ﬂow rate simulated the transit time in the
infant proximal colon, which is estimated to be a total transit time of 17.4 h in formula-fed infants aged
113 days (33). After an initial IR stabilization of 5 or 7 days for F1 and F2, respectively, the CR and TRs were
connected and operated in continuous mode with the same proximal colon conditions as the IR.
The IR and CR were operated with constant conditions of pH 6.0 and 5-h RT throughout the
fermentation time, which was 79 and 57 days for F1 and F2, respectively. Detailed experimental
conditions for the two PolyFermS fermentations are depicted in Fig. 1b. After initial stabilization times of
9 and 11 days in F1 and F2, respectively, the fermentations were divided into two periods. During period
1, the effects of pH and RT were studied, while the effects of lactate and LUB on composition and activity
of infant gut microbiota were investigated during period 2. Each period consisted of stabilization at pH
6 and a 5-h RT, which was followed by treatment. During treatment 1, combinations of pH (5 or 7) and
RT (5 h or 10 h) were assigned to TRs. The pHs (5.0 and 7.0) were chosen to simulate the colonic pH of
breast-fed (fecal pH of 5.1 to 5.4 in the ﬁrst 6 weeks) and formula-fed (fecal pH of 7.0 to 8.2 from the
second to the ﬁfth week; fecal pH of 6.4 after the ﬁfth week) infants, respectively (19). During treatment
2, DL-lactate was added in all TRs to achieve a concentration of 60 mM, with or without daily addition of
E. limosum (108 CFU ml1) and P. avidum (1 108 or 5 108 CFU ml1).
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Sampling of efﬂuents from all reactors was performed daily. The sample supernatant (10,000 rpm for
10 min) was used for HPLC analysis, while the pellet was stored at 80°C for DNA extraction. HPLC and
qPCR were performed on samples collected during the last 3 days of each stabilization and treatment.
MiSeq sequencing was performed on pooled samples collected during the last 2 days of the periods.
Plate counts of P. avidum were performed in triplicate on samples collected during the last 3 days of
stabilization, P. avidum treatment, and posttreatment periods (F2).
Sampling and analysis. (i) DNA extraction. Total genomic DNA was extracted from 200 mg fresh
infant feces and the pellet from 2ml of fermentation efﬂuent samples using the FastDNA Spin kit for soil
(MP Biomedicals, Illkirch, France) according to the manufacturer’s instructions. DNA concentration and
quality were assessed by absorbance measurements at 260 nm on a NanoDrop ND-1000 spectropho-
tometer (Witec AG, Littau, Switzerland), and samples were stored at 20°C before qPCR and MiSeq
sequencing analyses.
(ii) qPCR analysis. qPCR was performed using an ABI Prism 7500 PCR sequence detection system
(Applied Biosystems, Zug, Switzerland). Speciﬁc primers targeting predominant bacterial groups or
species in the infant gut were used at a ﬁnal concentration of 0.2 M (see Table S1 in the supplemental
material). Ampliﬁcation conditions were described previously (4).
(iii) MiSeq sequencing analysis. V3-V4 amplicons were prepared using speciﬁc forward primer F340
(5=-CCTACGGRAGGCAGCAG-3=) and reverse primer R805 (5=-GGACTACHVGGGTWTCTAAT-3=). Illumina
MiSeq sequencing analyses of fecal and efﬂuent samples were carried out at Genotoul (Toulouse, France).
Thermocycling was performed with an initial step at 94°C for 60 s, followed by 30 cycles of denaturation
at 94°C for 60 s, annealing at 65°C for 60 s, and elongation at 72°C for 60 s, with a ﬁnal elongation of
10 min at 72°C. The raw data set containing paired-end reads with corresponding quality scores was
merged and trimmed using settings as previously mentioned (51). Quantitative Insight Into Microbial
Ecology (QIIME) open source software (1.7.0 and 1.8.0) was used for subsequent analysis steps. Purging
the data set from chimeric reads and constructing de novo operational taxonomic units (OTU) were
conducted using the UPARSE pipeline. The HIT 16S rRNA gene collection was used as a reference
database.
Enumeration of P. avidum. Due to the lack of speciﬁc primers for Propionibacterium ampliﬁcation
by qPCR, P. avidum was enumerated in duplicate by plating 100 l of efﬂuent sample, which had been
serially diluted 10-fold, on 1.5% sodium lactate agar supplemented with metronidazole (4 mg liter1) and
kanamycin (10 mg liter1) (both from Sigma-Aldrich, Buchs, Switzerland) (52). Antibiotics were used to
obtain a higher degree of selectivity for Propionibacterium spp., as metronidazole is active against other
anaerobic microorganisms (53), such as Veillonella species (54), and kanamycin inhibits most Gram-
negative (such as Escherichia coli) and some Gram-positive bacteria (55, 56). A combination of kanamycin
and metronidazole allows differentiation of P. avidum, which forms smooth, cream- to orange-colored
convex and circular colonies of various sizes (57). Plates were incubated for 5 days in anaerobic jars at
37°C, and cell counts were reported as log CFU ml1 efﬂuent.
Metabolite analysis. The concentrations of SCFAs (acetate, propionate, butyrate, valerate, isobu-
tyrate, and isovalerate), formate, and DL-lactate in efﬂuent samples from all reactors were determined by
HPLC analysis. Supernatants from efﬂuent samples were passed through 0.45-m nylon HPLC ﬁlters
(Infochroma AG, Zug, Switzerland) before injection. HPLC analysis (Thermo Fisher Scientiﬁc Inc. Accela,
Wohlen, Switzerland) was performed as described previously (4). Data were expressed as mmol liter1
efﬂuent (mM).
L-Lactate concentration was measured by an enzymatic kit according to the manufacturer’s instruc-
tions (Megazyme, Bray, Co. Wicklow, Ireland). D-Lactate concentration was determined by subtracting
L-lactate concentration from total DL-lactate concentration.
Statistical analysis. Statistical analysis was done using IBM SPSS Statistics 20.0 (IBM Inc., Chicago, IL,
USA). qPCR (log10-transformed) and HPLC data were expressed as the mean results  SD for the last 3
days of each fermentation period and compared pairwise between stabilization and treatment within
each TR, using repeated-measures ANOVA. Comparisons between reactors within each fermentation
period were performed using ANOVA after testing for normal distribution using the Shapiro-Wilk test.
We combined SCFA concentrations and bacterial population levels from the two fermentations for
statistical analysis as follows. Differences (delta) between treatment and stabilization period within each
reactor were calculated for each combination of 3 measurement days, resulting in 9 delta values per
fermentation. Delta values between treatment (TR1 to TR4) and control (CR) reactors were compared
using the Wilcoxon rank sum test with false-discovery rate correction. Pairwise comparisons of SCFA
concentrations and bacterial population levels between each treatment reactor (TR1 to TR4) and control
reactor (CR) during stabilization periods were carried out using the Wilcoxon rank sum test with
false-discovery rate correction. For all tests, P values  0.05 were considered signiﬁcant.
Data availability. The sequence data reported in this paper have been deposited in the European
Nucleotide Archive database (accession no. PRJEB32244).
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